Skip to main content
. 2009 Feb 6;2:233–243. doi: 10.2147/dddt.s3181

Table 1.

Phase 2 data for nilotinib second-line to imatinib failure

Disease N % Response
Cytogenetic response
CHR Major Complete Overall survival
CML chronic 321 77 57 41 91% (18 months)
CML accelerated 136 26 31 19 81% (12 months)
CML blastic 136 11 40 29 42% (12 months)

Abbreviations: CHR, complete hematologic response; CML, chronic myeloid leukemia; ALL, acute lymphoid leukemia; Ph, Philadelphia chromosome.